BIO-RAD LABORATORIES acquisition history

Stilla Technologies is a commercial-stage life science company that develops and markets next-generation droplet digital PCR (Polymerase Chain Reaction) systems supporting a broad range of genetic and molecular testing applications. approximately $257.7 million purchase consideration ($166.5M cash to sellers, $47.6M cash paid to debtors on Stilla's behalf, $15.0M to escrow, plus $28.6M fair value of contingent consideration of up to $50.0M).

Stilla is a commercial-stage life science company that develops and markets next-generation droplet digital Polymerase Chain Reaction (PCR) systems, which supports a broad range of genetic and molecular testing applications.Bio-Rad Laboratories FY2025 10-K — Acquisitions note

Curiosity Diagnostics is a late-stage, pre-commercial platform company developing a sample-to-answer, rapid diagnostics PCR system for the molecular diagnostics market. $137.1 million total consideration, including fair value of contingent consideration of up to $70.0 million payable on technological development and sales milestones.

Curiosity Diagnostics, a late-stage, pre-commercial platform company, is in the process of developing a sample-to-answer, rapid diagnostics PCR system for the molecular diagnostics market.Bio-Rad Laboratories FY2022 10-K — Acquisition note

Dropworks is a development-stage company focused on developing a digital PCR product. $125.5 million total consideration.

Dropworks is a development stage company focused on developing a digital PCR product. The strategic rationale for the transaction was to address additional opportunities in the PCR market.Bio-Rad Laboratories FY2021 10-K — Acquisition note

Celsee is a manufacturer of instruments and consumables for the isolation, detection, and analysis of single cells. $99.3 million total consideration, including fair value of contingent consideration of up to $60.0 million payable on certain 2021-2022 net-revenue achievement.

Celsee is a manufacturer of instruments and consumables for the isolation, detection, and analysis of single cells. We believe this acquisition will complement our Life Science product offerings.Bio-Rad Laboratories FY2020 10-K — Acquisitions note

RainDance Technologies' foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research, enabling ultra-sensitive detection of genetic variations. approximately $72.7 million (cash payments at closing of $72.9 million; a separate $10.0 million cash payment for a preexisting condition was recorded in cost of goods sold).

RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets... These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy.Bio-Rad Laboratories FY2018 10-K — Acquisition of RainDance Technologies note

GnuBIO's innovative DNA workflow is well-suited for the clinical diagnostics sequencing market and leverages droplet digital PCR technology. $50.4 million total consideration ($39.7 million cash at closing plus $10.7 million contingent consideration, potentially up to $70.0 million on development/regulatory and sales milestones).

We believe that GnuBIO's innovative DNA workflow is well-suited for the clinical diagnostics sequencing market and will leverage our leadership role in the area of droplet digital PCR.Bio-Rad Laboratories FY2014 10-K — acquisitions disclosure

AbD Serotec, acquired from MorphoSys AG, brought a comprehensive catalog of research antibodies to Bio-Rad's Life Science business. $62.2 million total consideration (net of cash received of $7.3 million).

In January 2013, we acquired 100% of the outstanding shares of AbD Serotec, a division of MorphoSys AG, for total consideration of $62.2 million (net of cash received of $7.3 million).Bio-Rad Laboratories FY2013 10-K — acquisitions disclosure

QuantaLife developed droplet digital PCR technology that became the foundation of Bio-Rad's droplet digital PCR (ddPCR) systems. $179.4 million fair value of consideration ($150.3 million cash at closing, $5.0 million holdback, $24.1 million contingent consideration; contingent portion could reach $48 million on sales and development milestones).

In October 2011, we acquired all the issued and outstanding stock of QuantaLife, Inc. The fair value of the consideration as of the acquisition date was $179.4 million, which comprised of $150.3 million paid in cash at the closing date, a $5.0 million holdback... and $24.1 million in contingent consideration.Bio-Rad Laboratories FY2011 10-K — acquisitions disclosure

DiaMed develops, manufactures and markets a complete line of reagents and instruments used in blood typing and screening. Founded in 1977 and based in Switzerland, DiaMed had annual sales of approximately US $200 million to hospitals, clinical laboratories, and blood banks in more than 100 countries, with nearly 800 employees. approximately 477 million Swiss francs in cash for ~77.7% of shares (with a subsequent tender offer for the remaining ~12.7%).

DiaMed has an outstanding reputation for quality products and customer care and we believe this portfolio of products will fit in well with Bio-Rad's existing diagnostics business.John Goetz — Vice President and Group Manager Clinical Diagnostics, Bio-Rad Laboratories

In August 2012, Bio-Rad acquired from Propel Labs, Inc. a new cell sorting system. $5.0 million in cash at closing (plus contingent consideration recognized for the cell sorting system).

In August 2012, we acquired from Propel Labs, Inc. a new cell sorting system that included $5.0 million in cash at the closing date.Bio-Rad Laboratories FY2014 10-K — acquisitions disclosure

In July 2012, Bio-Rad acquired all of the outstanding shares of DiaMed Benelux, extending its DiaMed blood-typing diagnostics franchise in the Benelux region. 4.6 million Euros (approximately $5.6 million) in cash.

In July 2012, we acquired all of the outstanding shares of DiaMed Benelux for 4.6 million Euros (approximately $5.6 million) in cash.Bio-Rad Laboratories FY2014 10-K — acquisitions disclosure